HSBC Holdings
PTGX icon

HSBC Holdings’s Protagonist Therapeutics PTGX Stock Holding History

HSBC Holdings’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$201K Buy
+1,907
New +$169K ﹤0.01% 2615
2025
Q3 		– Sell
-4,340
Closed -$242K – 3053
2025
Q2 		$242K Sell
4,340
-4,118
-49% -$198K ﹤0.01% 2581
2025
Q1 		$405K Buy
8,458
+330
+4% +$13.8K ﹤0.01% 2188
2024
Q4 		$313K Buy
8,128
+2,259
+38% +$98.5K ﹤0.01% 2476
2024
Q3 		$262K Sell
5,869
-1,660
-22% -$67.1K ﹤0.01% 2438
2024
Q2 		$257K Sell
7,529
-105,358
-93% -$3.09M ﹤0.01% 2395
2024
Q1 		$3.27M Sell
112,887
-6,447
-5% -$175K ﹤0.01% 1272
2023
Q4 		$2.74M Sell
119,334
-434,971
-78% -$7.61M ﹤0.01% 1365
2023
Q3 		$9.17M Sell
554,305
-6,150
-1% -$119K 0.01% 857
2023
Q2 		$15.7M Buy
+560,455
New +$14M 0.02% 685

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

HSBC Holdings's PTGX Position: Q1 2026 in Review

HSBC Holdings opened a new position in Protagonist Therapeutics (PTGX) in Q1 2026: 1,907 shares worth $201K. The stake represents ﹤0.01% of the portfolio and ranks #2615 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in PTGX as recently as Q2 2025.

HSBC Holdings first reported a position in PTGX in Q2 2023 and has held it in 10 quarters since. The position peaked at $15.7M in Q2 2023. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • HSBC Holdings held 1,907 shares of Protagonist Therapeutics worth $201K as of Q1 2026.
  • Protagonist Therapeutics was a new HSBC Holdings position in Q1 2026.
  • Protagonist Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2615 holding.
  • HSBC Holdings first reported a position in Protagonist Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • HSBC Holdings's Protagonist Therapeutics position peaked at $15.7M in Q2 2023.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.